Detalhe da pesquisa
1.
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Lancet Oncol
; 22(11): 1618-1631, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34678156
2.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 19(4): 562-578, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29611518
3.
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
Br J Cancer
; 119(11): 1332-1338, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30420616
4.
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Health Technol Assess
; 23(64): 1-88, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31852579
5.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
J Clin Oncol
; 20(16): 3533-44, 2002 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12177114
6.
Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Urol Oncol
; 33(8): 337.e1-6, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26092557